Agile is designed to trial as many drugs as possible, no matter the trial phase, and the least amount of data points (patients and trial arms). AGILE does not want a wonder drug to test across all areas of the globe. The goal is the compare drugs and not to find the best drug with the most data points.
We don't know what we don't know, but I think the market has got this all wrong.
Can anybody tell me why trialingl paxalisib to more parient numbers is better? Given yhat it is safe and extends life...
